International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Purpose
Most patients with acute myeloid leukemia (AML) eventually experience relapse. Relapsed/refractory AML has a dismal prognosis and currently available treatment options are generally ineffective. The objective of this large, international, randomized clinical trial was to investigate the efficacy of elacytarabine, a novel elaidic acid ester of cytarabine, versus the investigator's choice of one of seven commonly used AML salvage regimens, including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxyurea, and supportive care.
Patients and Methods
A total of 381 patients with relapsed/refractory AML were treated in North America, Europe, and Australia. Investigators selected a control treatment for individual patients before random assignment. The primary end point was overall survival (OS).
Results
There were no significant differences in OS (3.5 v 3.3 months), response rate (23% v 21%), or relapse-free survival (5.1 v 3.7 months) between the elacytarabine and control arms, respectively. There was no significant difference in OS among any of the investigator's choice regimens. Prolonged survival was only achieved in a few patients in both study arms whose disease responded and who underwent allogeneic stem-cell transplantation.
Conclusion
Neither elacytarabine nor any of the seven alternative treatment regimens provided clinically meaningful benefit to these patients. OS in both study arms and for all treatments was extremely poor. Novel agents, novel clinical trial designs, and novel strategies of drug development are all desperately needed for this patient population.
Топ-30
Журналы
|
2
4
6
8
10
12
|
|
|
Blood
11 публикаций, 6.59%
|
|
|
Cancer
7 публикаций, 4.19%
|
|
|
Blood advances
7 публикаций, 4.19%
|
|
|
Leukemia and Lymphoma
6 публикаций, 3.59%
|
|
|
Leukemia Research
6 публикаций, 3.59%
|
|
|
British Journal of Haematology
6 публикаций, 3.59%
|
|
|
American Journal of Hematology
6 публикаций, 3.59%
|
|
|
The Lancet Oncology
4 публикации, 2.4%
|
|
|
Future Oncology
3 публикации, 1.8%
|
|
|
Therapeutic Advances in Hematology
3 публикации, 1.8%
|
|
|
Journal of Clinical Medicine
3 публикации, 1.8%
|
|
|
Blood Cancer Journal
3 публикации, 1.8%
|
|
|
Annals of Hematology
3 публикации, 1.8%
|
|
|
Best Practice and Research in Clinical Haematology
3 публикации, 1.8%
|
|
|
Journal of Controlled Release
3 публикации, 1.8%
|
|
|
Clinical Lymphoma, Myeloma and Leukemia
3 публикации, 1.8%
|
|
|
New England Journal of Medicine
2 публикации, 1.2%
|
|
|
Current Opinion in Hematology
2 публикации, 1.2%
|
|
|
Cancers
2 публикации, 1.2%
|
|
|
Molecules
2 публикации, 1.2%
|
|
|
Frontiers in Oncology
2 публикации, 1.2%
|
|
|
Journal of Cancer Research and Clinical Oncology
2 публикации, 1.2%
|
|
|
Nature Communications
2 публикации, 1.2%
|
|
|
Leukemia
2 публикации, 1.2%
|
|
|
Biomarker Research
2 публикации, 1.2%
|
|
|
Blood Reviews
2 публикации, 1.2%
|
|
|
Hematology
2 публикации, 1.2%
|
|
|
European Journal of Haematology
2 публикации, 1.2%
|
|
|
Expert Opinion on Pharmacotherapy
2 публикации, 1.2%
|
|
|
2
4
6
8
10
12
|
Издатели
|
5
10
15
20
25
30
35
|
|
|
Elsevier
33 публикации, 19.76%
|
|
|
Wiley
27 публикаций, 16.17%
|
|
|
Springer Nature
25 публикаций, 14.97%
|
|
|
American Society of Hematology
20 публикаций, 11.98%
|
|
|
Taylor & Francis
18 публикаций, 10.78%
|
|
|
MDPI
9 публикаций, 5.39%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
5 публикаций, 2.99%
|
|
|
Frontiers Media S.A.
4 публикации, 2.4%
|
|
|
SAGE
3 публикации, 1.8%
|
|
|
American Association for Cancer Research (AACR)
3 публикации, 1.8%
|
|
|
American Society of Clinical Oncology (ASCO)
3 публикации, 1.8%
|
|
|
Massachusetts Medical Society
2 публикации, 1.2%
|
|
|
American Chemical Society (ACS)
2 публикации, 1.2%
|
|
|
Cold Spring Harbor Laboratory
2 публикации, 1.2%
|
|
|
Bentham Science Publishers Ltd.
1 публикация, 0.6%
|
|
|
Impact Journals
1 публикация, 0.6%
|
|
|
1 публикация, 0.6%
|
|
|
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
1 публикация, 0.6%
|
|
|
Neoplasia Press
1 публикация, 0.6%
|
|
|
Society for Translational Oncology
1 публикация, 0.6%
|
|
|
Walter de Gruyter
1 публикация, 0.6%
|
|
|
Japanese Pharmacological Society
1 публикация, 0.6%
|
|
|
The Japan Society for Hematopoietic Stem Cell Transplantation
1 публикация, 0.6%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 0.6%
|
|
|
5
10
15
20
25
30
35
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.